---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-000435"
form_type: "8-K"
ticker: "IONS"
cik: "0000874015"
company_name: "IONIS PHARMACEUTICALS INC"
filed_at: "2026-01-07T23:59:59+00:00"
generated_at: "2026-05-16T11:28:47.781995+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Bepirovirsen Phase 3 positive: primary endpoint met, functional cure rates superior to SOC

## Summary
- Over 1,800 patients enrolled in two Phase 3 studies (B-Well 1 & 2) across 29 countries.
- Bepirovirsen + SOC achieved statistically significant functional cure rates vs. SOC alone on all ranked endpoints.
- Ionis eligible for up to $150M in regulatory/sales milestones plus 10-12% tiered royalties.
- Global regulatory submissions planned from Q1 2026; potential first finite 6-month CHB therapy.
- Drug has Fast Track FDA, Breakthrough Therapy China, and SENKU Japan designations.

## SEC filing metadata
- accession: 0001140361-26-000435
- form_type: 8-K
- ticker: IONS
- cik: 0000874015
- company_name: IONIS PHARMACEUTICALS INC
- filed_at: 2026-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/0001140361-26-000435-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/874015/000114036126000435/ef20062477_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-000435
- JSON: https://secwatch.observer/filing/0001140361-26-000435.json
- Plain text: https://secwatch.observer/filing/0001140361-26-000435.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.